IRAK1BP1 and prostate adenocarcinoma: The differential expression of IRAK1BP1 is again evident in LUAD and LUSC, the two main NSCLC subtypes (red box); IRAK1BP1 expression is lower in tumor relative to normal tissue in many other cancer types such as breast cancer (BRCA), kidney cancers (KICH, KIRC), and prostate adenocarcinoma (PRAD); while in some cancer types, such as cholaniocarcinoma (CHOL) and colon adenocarcinoma (COAD), the opposite is true (Figure 1G).